These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23639138)

  • 1. Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.
    Rao NP; Remington G
    Expert Opin Investig Drugs; 2013 Jul; 22(7):881-94. PubMed ID: 23639138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.
    Rao NP; Remington G
    Expert Opin Pharmacother; 2014 Feb; 15(3):373-83. PubMed ID: 24354659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational dopamine antagonists for the treatment of schizophrenia.
    Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
    Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs in development for the treatment of schizophrenia.
    Emsley R
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1103-18. PubMed ID: 19589093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.
    Remington G; Agid O; Foussias G
    Expert Rev Neurother; 2011 Apr; 11(4):589-607. PubMed ID: 21469931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
    Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
    Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
    Tsai SJ
    Med Hypotheses; 2004; 63(6):1047-50. PubMed ID: 15504573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials.
    Miyamoto S; Jarskog LF; Fleischhacker WW
    Curr Opin Psychiatry; 2013 Mar; 26(2):158-65. PubMed ID: 23286991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?
    Ellenbroek BA
    Neuropharmacology; 2012 Mar; 62(3):1371-80. PubMed ID: 21420988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors.
    Li X; Ma S
    Curr Drug Targets; 2013 Jul; 14(8):899-918. PubMed ID: 23701299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.
    Citrome L
    CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia.
    Wallace TL; Bertrand D
    Expert Opin Ther Targets; 2013 Feb; 17(2):139-55. PubMed ID: 23231385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for schizophrenia: an update.
    Köster LS; Carbon M; Correll CU
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):511-31. PubMed ID: 25234340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic approaches to cognitive enhancement in schizophrenia.
    Burdick KE; Gopin CB; Malhotra AK
    Harv Rev Psychiatry; 2011; 19(3):102-8. PubMed ID: 21631157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and solutions in developing new medications for Schizophrenia.
    J Clin Psychiatry; 2010 Oct; 71(10):1391-9. PubMed ID: 21062617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.